Johnson & Johnson's Janssen Biotech will end a licensing partnership with Geron Corp., returning rights to the biotech’s sole product candidate, imetelstat.
Janssen had entered into the agreement in 2014 with California-based Geron to develop and commercialize imetelstat in oncology, including hematologic myeloid malignancies.
According to Janssen’s press release, the decision not to continue the collaboration is the “result of a strategic portfolio evaluation and prioritization of assets within the robust Janssen portfolio.”
Bloomberg reports that the move wiped out $750 million in market value for Geron.
[javascriptSnippet]